A separate analysis using the DepMap PRISM repurposing Primary Screen [52] confirmed the potential to target MEK as it identified Tramatenib (GSK1120212) a MEK1/2 inhibitor FDA approved for the treatment of BRAF-mutated advanced NSCLC [61], and currently in a Phase I trial for KRAS mutated NSCLC [62]. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.